Prescribing Guides
Ethambutol Prescribing Guide for Indian Clinical Practice
Ethambutol prescribing guide for Indian clinicians covering its role in preventing resistance, ocular toxicity monitoring, dosing and NEET PG pharmacology.
MedNext Editorial Team | 2026-08-01 | 8 min read
Ethambutol Prescribing Guide for Indian Clinical Practice
Ethambutol prescribing guide for Indian clinicians covering its role in preventing resistance, ocular toxicity monitoring, dosing and NEET PG pharmacology.
Ethambutol is a bacteriostatic anti-TB drug that serves as a companion agent to prevent resistance emergence during the intensive phase of tuberculosis treatment. Its dose-dependent ocular toxicity requires careful monitoring.
Clinical Pharmacology Overview
Ethambutol inhibits arabinosyl transferase (encoded by the embB gene), an enzyme involved in the synthesis of arabinogalactan, a key component of the mycobacterial cell wall. This disrupts cell wall integrity but does not kill the bacteria, making ethambutol bacteriostatic rather than bactericidal.
Pharmacokinetics: Well absorbed orally (bioavailability 75-80%). Protein binding is 20-30%. Distributed well to most tissues including lungs and kidneys but has limited CSF penetration (poor in non-inflamed meninges). Half-life is 3-4 hours. Primarily renally excreted (80% unchanged in urine). Accumulates in renal impairment.
Indian Brand Names
- Myambutol (Lupin)
- Combutol (Lupin)
- Ethambutol IP (generic, NTEP supply)
- Available predominantly in FDC formulations under NTEP
Approved Indications in Indian Clinical Practice
- Drug-sensitive tuberculosis (intensive phase -- first 2 months, as part of HRZE)
- Some MDR-TB regimens
- Non-tuberculous mycobacterial (NTM) infections (e.g., MAC -- in combination with macrolides)
Dosing in Adults
NTEP daily regimen: 15-20 mg/kg/day as part of FDC.
30-39 kg: 550 mg daily 40-54 kg: 800 mg daily 55-69 kg: 1100 mg daily 70 kg and above: 1400 mg daily
Duration: first 2 months in drug-sensitive TB (intensive phase). Some protocols extend to the continuation phase.
Can be taken with or without food.
NTM (MAC): 15 mg/kg/day (usually 800-1200 mg) as part of combination therapy for prolonged duration.
Important Drug Interactions
- Aluminium-containing antacids: reduce ethambutol absorption (separate by 4 hours)
- Other nephrotoxic drugs: increased risk of accumulation and toxicity
- Few significant pharmacokinetic drug interactions (does not affect CYP enzymes)
Side Effects and Monitoring
Common: GI upset, headache, dizziness, rash.
Serious: optic neuritis (retrobulbar neuritis) -- the most important adverse effect. Dose-dependent: risk is low at 15 mg/kg/day, significant at doses above 25 mg/kg/day. Presents with decreased visual acuity, central scotoma, loss of red-green colour discrimination. Usually reversible if detected early.
Other: peripheral neuropathy, hyperuricaemia (mild, due to reduced renal urate excretion).
Monitoring: - Baseline visual acuity (Snellen chart) and colour vision (Ishihara plates) BEFORE starting treatment - Monthly visual acuity and colour vision testing during treatment - Educate patient to report any visual changes immediately - Renal function at baseline and periodically (drug accumulates in renal impairment)
Special Populations
Pregnancy: Category B (previously C). Considered safe in pregnancy. Included in standard NTEP regimen for pregnant women.
Renal impairment: Dose reduction or increased dosing interval required. For GFR 10-50: 15 mg/kg every 24-36 hours. For GFR less than 10: 15 mg/kg every 48 hours. Monitor closely for ocular toxicity as accumulation increases risk.
Hepatic impairment: No dose adjustment needed (renally excreted).
Children: 20 mg/kg/day (WHO and NTEP recommendation). Now included in paediatric TB regimens. Counsel parents to watch for visual complaints.
Elderly: Higher risk of ocular toxicity (pre-existing visual impairment, renal decline). Monitor closely.
NEET PG High-Yield Points
- Inhibits arabinosyl transferase (embB gene) -- disrupts arabinogalactan synthesis
- BACTERIOSTATIC (not bactericidal) -- companion drug to prevent resistance
- Optic neuritis (retrobulbar): decreased visual acuity, red-green colour blindness, central scotoma
- Dose-dependent: risk increases above 25 mg/kg/day
- Check visual acuity and colour vision BEFORE starting treatment
- Poor CSF penetration -- limited role in TB meningitis
- Primarily renally excreted -- accumulates in renal failure
- embB mutation = mechanism of ethambutol resistance
- Only bacteriostatic drug in the standard HRZE regimen
Indian Regulatory Status
Ethambutol is a Schedule H drug under the Drugs and Cosmetics Act. It is included in the NLEM of India. Under the NTEP, it is supplied as part of the 4-drug FDC (HRZE) for the intensive phase. Single-drug formulations are available for NTM infections. The CDSCO mandates visual monitoring during ethambutol therapy.
Frequently Asked Questions
Why is ethambutol included in the TB regimen?
Ethambutol is included primarily to prevent the emergence of resistance to rifampicin and isoniazid during the intensive phase. In areas with high rates of primary INH resistance (like India, where rates are 10-15%), ethambutol provides a protective companion drug. It is bacteriostatic and does not contribute significant sterilising activity.
What is the ocular toxicity of ethambutol?
Ethambutol causes dose-dependent optic neuritis (retrobulbar neuritis), presenting as decreased visual acuity, loss of red-green colour discrimination, and central scotoma. Risk is significant at doses above 25 mg/kg/day and with prolonged use. Visual symptoms are usually reversible if detected early and the drug is stopped, but can be irreversible if continued.
How should visual acuity be monitored?
Baseline visual acuity and colour vision testing (Ishihara charts) before starting ethambutol. Monthly monitoring during treatment. Patients must be instructed to report any visual changes immediately. In patients unable to report visual changes (young children, mentally impaired), ethambutol use requires careful risk-benefit assessment.
Can ethambutol be used in children?
Previously avoided in young children due to difficulty monitoring visual acuity, ethambutol is now recommended by WHO and NTEP in children at 20 mg/kg/day. The risk of ocular toxicity at recommended doses for 2 months is low. Parents should be counselled to watch for visual complaints.
Continue reading
Prescribing GuidesMetformin Prescribing Guide for Indian Clinical Practice
Evidence-based metformin prescribing for Indian clinicians covering dosing, brands, interactions, monitoring and NEET PG high-yield points.
Prescribing GuidesCeftriaxone Prescribing Guide for Indian Clinical Practice
Complete ceftriaxone prescribing reference for Indian clinicians covering indications, dosing, reconstitution, drug interactions and NEET PG points.
Prescribing GuidesAmoxicillin Prescribing Guide for Indian Clinical Practice
Comprehensive amoxicillin prescribing reference for Indian doctors covering dosing, brands, resistance patterns and NEET PG high-yield pharmacology.
Continue with Prescribing Guides
Apply what you have read with clinical prescribing MCQs that test real decision-making: drug choice, dose selection, interactions and monitoring.
Try prescribing questionsBrowse all prescribing guides